Table 4 Cytotoxic chemotherapies administered as first-line therapy for metastatic breast cancer (FAS)
gBRCAm status | |||
|---|---|---|---|
Positive (N = 33) | Negative (N = 308) | FAS (N = 341) | |
Number of unique agents received as first-line therapy, n (%)* | |||
1 | 15 (45.5) | 181 (58.8) | 196 (57.5) |
2 | 15 (45.5) | 105 (34.1) | 120 (35.2) |
3 | 1 (3.0) | 16 (5.2) | 17 (5.0) |
4+ | 2 (6.1) | 6 (1.9) | 8 (2.3) |
Cytotoxic chemotherapy agent (in > 5% of patients), n (%)* | |||
Paclitaxel | 12 (36.4) | 115 (37.3) | 127 (37.2) |
Cyclophosphamide | 5 (15.2) | 55 (17.9) | 60 (17.6) |
Capecitabine | 7 (21.2) | 50 (16.2) | 57 (16.7) |
Docetaxel | 6 (18.2) | 42 (13.6) | 48 (14.1) |
Carboplatin | 5 (15.2) | 26 (8.4) | 31 (9.1) |
Doxorubicin | 3 (9.1) | 26 (8.4) | 29 (8.5) |
Gemcitabine | 4 (12.1) | 24 (7.8) | 28 (8.2) |
Bevacizumab | 4 (12.1) | 22 (7.1) | 26 (7.6) |
Cisplatin | 1 (3.0) | 22 (7.1) | 23 (6.7) |
Epirubicin | 2 (6.1) | 19 (6.2) | 21 (6.2) |